CFR Raises Offer for Adcock by 2% as Shareholder Vote Delayed

CFR Pharmaceuticals SA (CFR), Chile’s largest drug developer, raised its offer to buy South African drugmaker Adcock Ingram Holdings Ltd. (AIP) by 2 percent to 12.8 billion rand ($1.2 billion), days before Adcock shareholders were to vote on its previous offer.

CFR is now proposing an offer valued at 74.5 rand to 75.78 rand per share, with a minimum of 50 percent to be paid in cash, Johannesburg-based Adcock said in a statement today. Its previous cash and stock offer valued the company at about 75 rand a share, Adcock said Dec. 3.

Adcock shares rose as much as 2.8 percent, the most on an intraday basis in almost a month, and traded 0.9 percent higher at 70.60 rand by 2:53 p.m. in Johannesburg.

A consortium led by Bidvest Group Ltd. (BVT), South Africa’s second-biggest company by revenue, made an all-cash offer of 70 rand a share to buy a 34.5 percent stake in Adcock on Dec. 2. Shareholders were scheduled to vote on Santiago-based CFR’s previous 12.6 billion rand bid on Dec. 18. A new date for the meeting will now be scheduled for about the end of January. Both CFR proposals have been recommended by the Adcock board.

The Public Investment Corp., a manager of South African civil servant pension funds which holds almost 20 percent of Adcock, hadn’t given its support for the previous CFR deal. PIC was seeking an all-cash offer of as much as 74 rand, a person familiar with the matter said Dec. 5.

Daniel Matjila, chief investment officer for the PIC, wasn’t immediately available to comment. Julian Gwillim, a spokesman for Bidvest, didn’t immediately respond to calls seeking comment.

To contact the reporters on this story: Janice Kew in Johannesburg at; Christopher Spillane in Johannesburg at

To contact the editor responsible for this story: Celeste Perri at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.